This Article Full Text Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Strony, J. Articles by Adelman, B. Search for Related Content PubMed PubMed Citation Articles by Strony, J. Articles by Adelman, B. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1995;15:359-366.)
© 1995 American Heart Association, Inc.

Articles

Aurintricarboxylic Acid Prevents Acute Rethrombosis in a Canine Model of Arterial Thrombosis

John Strony; Anly Song; Lori Rusterholtz; Burt Adelman

From the Department of Medicine, Division of Cardiology, Case Western Reserve University Hospitals, and the Department of Veterans Affairs Medical Center, Cleveland, Ohio (J.S., L.R.); the Department of Medicine, Medical College of Virginia, Richmond (A.S.); and the Department of Medicine, Division of Hematology, Medical College of Virginia, and the Department of Veterans Affairs Medical Center, Richmond (B.A.).

Correspondence to John Strony, MD, Case Western Reserve University Hospitals of Cleveland, 11100 Euclid Ave, Cleveland, OH 44106.

Abstract Acute rethrombosis following thrombolytic therapy occurs in 5% to 25% of patients. We evaluated the effect of aurintricarboxylic acid (ATA), a triphenyl dye that blocks von Willebrand factor (vWF) binding to platelet glycoprotein Ib, on arterial reperfusion and acute rethrombosis following fibrinolytic therapy. Primary thrombosis was induced in the femoral arteries of anesthetized dogs by application of anodal current and partial arterial constriction. Blood flow was monitored with an electromagnetic flow probe, and primary thrombosis was considered to have occurred when blood flow was reduced to and remained at zero. Reperfusion was induced by intravenous streptokinase 30 minutes after thrombosis. Streptokinase reduced plasma fibrinogen levels from an average of 144 mg/dL to <5 mg/dL resulting in inhibition of ADP- and epinephrine-induced platelet aggregation ex vivo. Acute rethrombosis following reperfusion occurred within 37±18 (mean±SD) minutes in 89% (16/18) of animals receiving thrombolytic activator treatment. Histological examination of reoccluding thrombi revealed densely aggregated platelets and erythrocytes with no detectable fibrin. In the two other study groups, ATA was infused in conjunction with thrombolytic therapy (10 arteries) or at near completion of acute rethrombosis following fibrinolytic activator treatment (6 arteries). In each case ATA prevented rethrombosis. However, concomitant administration of ATA and thrombolytic therapy delayed restoration of blood flow. ATA had no direct effect on hemodynamics, thrombin time, platelet count, or platelet aggregation response to ADP, epinephrine, or collagen. These data indicate that inhibition of vWF–platelet glycoprotein Ib interaction is effective in preventing acute rethrombosis following thrombolytic therapy. However, the complex paradoxical effects of ATA on platelet activity should be considered when it, or agents of its class, are used as antithrombotics.

Key Words: fibrinolysis • platelets • thrombosis • acute rethrombosis

This article has been cited by other articles:

				A. Inbal, O. Gurevitz, I. Tamarin, R. Eskaraev, A. Chetrit, I. Novicov, M. Feldman, D. Varon, M. Eldar, and J. Loscalzo Unique Antiplatelet Effects of a Novel S-Nitrosoderivative of a Recombinant Fragment of von Willebrand Factor, AR545C: In Vitro and Ex Vivo Inhibition of Platelet Function Blood, September 1, 1999; 94(5): 1693 - 1700. [Abstract] [Full Text] [PDF]

				S. Goto, H. Sakai, M. Goto, M. Ono, Y. Ikeda, S. Handa, and Z. M. Ruggeri Enhanced Shear-Induced Platelet Aggregation in Acute Myocardial Infarction Circulation, February 9, 1999; 99(5): 608 - 613. [Abstract] [Full Text] [PDF]

				R. Gonzalez-Conejero, M. L. Lozano, J. Rivera, J. Corral, J. A. Iniesta, J. M. Moraleda, and V. Vicente Polymorphisms of Platelet Membrane Glycoprotein Ibalpha Associated With Arterial Thrombotic Disease Blood, October 15, 1998; 92(8): 2771 - 2776. [Abstract] [Full Text] [PDF]

				M.-C. Chang, H.-K. Lin, H.-C. Peng, and T.-F. Huang Antithrombotic Effect of Crotalin, a Platelet Membrane Glycoprotein Ib Antagonist From Venom of Crotalus atrox Blood, March 1, 1998; 91(5): 1582 - 1589. [Abstract] [Full Text] [PDF]

				I. Escargueil-Blanc, O. Meilhac, M.-T. Pieraggi, J.-F. Arnal, R. Salvayre, and A. Negre-Salvayre Oxidized LDLs Induce Massive Apoptosis of Cultured Human Endothelial Cells Through a Calcium-Dependent Pathway: Prevention by Aurintricarboxylic Acid Arterioscler Thromb Vasc Biol, February 1, 1997; 17(2): 331 - 339. [Abstract] [Full Text]